Immune checkpoint inhibitors are a reality for the treatment of patients with NSCLC, and if approved for SCLC, would be a treatment breakthrough we have not seen for decades.
Leora Horn, MD, MSc
Advertisement
Articles by Leora Horn, MD, MSc
Advertisement
Latest Updated Articles
- Immune Checkpoint Inhibition in Lung Cancer: The Good, the Bad, and the Ugly
Published: August 15th 2016 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
2
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
3
Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL
4
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
5
